ataciguat
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00443287)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1- Mol. weight
- 576.51 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107729 ↗
Also known as
- 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-n-(4-(morpholine-4-sulfonyl)phenyl)benzamide
- ataciguat
- ataciguat
- ataciguat
- ataciguat
- ataciguat
- hmr1766
- hmr 1766
- hmr-1766
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02481258 | Phase 2 | Jun 1, 2015 | Mayo Clinic, National Institutes of Health (NIH), Sanofi |
| NCT02049203 | Phase 1 | Jan 1, 2014 | Mayo Clinic, National Center for Advancing Translational Science (NCATS), National Center for Research Resources (NCRR), Sanofi-Synthelabo |
| NCT00799656 | Phase 2 | Nov 1, 2008 | Sanofi |
| NCT00443287 | Phase 2 | Feb 1, 2007 | Sanofi |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 3 | 2 | 1 | 2007 |
| Mayo Clinic | Academic/Hospital | 2 | 2 | 2 | 2014 |
| National Center for Advancing Translational Science (NCATS) | Government | 1 | 0 | 1 | 2014 |
| National Center for Research Resources (NCRR) | Government | 1 | 0 | 1 | 2014 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2015 |
| Sanofi-Synthelabo | For profit | 1 | 0 | 1 | 2014 |
6 organizations
Page 1 / 1